Techniques in Regional Anesthesia & Pain Management
Volume 13, Issue 1 , Pages 28-37 , January 2009

Lifestyle changes, dietary restrictions, and nutraceuticals in migraine prevention

  • Frederick R. Taylor, MD, FAHS

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Frederick R. Taylor, MD, FAHS, Park-Nicollet Health Services, 6490 Excelsior Blvd E-500, Minneapolis, MN 55426

References 

  1. Rossi P, Di Lorenzo G, Malpezzi MG, et al. Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia. 2005;25:493–506
  2. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349
  3. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: The Disability in Strategies of Care (DISC) study: A randomized trial. J Am Med Assoc. 2000;284:2599–2605
  4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24(suppl 1):
  5. Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–89
  6. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. http://www.aan.com/practice/guideline/index.cfm?Fuseaction=home.welcome&Topics=16&keywords=&Submit=Search+GuidelinesAccessed November 21, 2008
  7. Edwards RR, Almeida DM, Klick B, et al. Duration of sleep contributes to next-day pain report in the general population. Pain. 2008;137:202–207
  8. Rains JC. Optimizing circadian cycles and behavioral insomnia treatment in migraine. Curr Pain Headache Rep. 2008;12:213–219
  9. Campbell JK, Penzien DB, Wall EM. Background/data: Evidence-based guidelines for migraine headache: Behavioral and physical treatments. http://www.aan.com/practice/guideline/index.cfm?fuseaction=home.welcome&Topics=16&keywords=&Submit=Search+GuidelinesAccessed November 21, 2008
  10. Long L, Huntley A, Ernst E. Which complementary and alternative therapies benefit which conditions? (A survey of the opinions of 223 professional organizations). Complement Ther Med. 2001;9:178–185
  11. Massiou H. Migraine medication attributes are important for patient compliance. Drugs Today (Barc). 2003;39(suppl D):25–29
  12. Termine C, Ginevra OF, D'Arrigo S, et al. Alternative therapies in the treatment of headache in childhood, adolescence and adulthood. Funct Neurol. 2005;20:9–14
  13. Schürks M, Kurth T, de Jesus J, et al. Cluster headache: Clinical presentation, lifestyle features, and medical treatment. Headache. 2006;46:1246–1254
  14. Hanington E, Harper AM. The role of tyramine in the aetiology of migraine, and related studies on the cerebral and extracerebral circulations. Headache. 1968;8:84–97
  15. García-Villar N, Saurina J, Hernández-Cassou S. High-performance liquid chromatographic determination of biogenic amines in wines with an experimental design optimization procedure. Anal Chim Acta. 2006;575:97–105
  16. Panconesi A. Alcohol and migraine: Trigger factor, consumption, mechanisms (A review). J Headache Pain. 2008;9:19–27
  17. Kanny G, Bauza T, Frémont S, et al. Histamine content does not influence the tolerance of wine in normal subjects. Allerg Immunol (Paris). 1999;31:45–48
  18. Kanny G, Gerbaux V, Olszewski A, et al. No correlation between wine intolerance and histamine content of wine. J Allerg Clin Immunol. 2001;107:375–378
  19. Jarman J, Pattichis K, Peatfield R, et al. Red wine-induced release of [14C]5-hydroxytryptamine from platelets of migraine patients and controls. Cephalalgia. 1996;16:41–43
  20. Littlewood JT, Gibb C, Glover V, et al. Red wine as a cause of migraine. Lancet. 1988;1:558–559
  21. Nicolodi M, Sicuteri F. Wine and migraine: Compatibility or incompatibility?. Drugs Exp Clin Res. 1999;25:147–153
  22. Schiffman SS, Buckley CE, Sampson HA, et al. Aspartame and susceptibility to headache. N Engl J Med. 1987;317:1181–1185
  23. Koehler SM, Glaros A. The effect of aspartame on migraine headache. Headache. 1988;28:10–14
  24. Van den Eeden SK, Koepsell TD, Longstreth WT, et al. Aspartame ingestion and headaches: A randomized crossover trial. Neurology. 1999;44:1787–1793
  25. Stegink LD, Filer LJ, Baker GL. Effect of aspartame and sucrose loading in glutamate-susceptible subjects. Am J Clin Nutr. 1981;34:1899–1905
  26. Reif-Lehrer L. A questionnaire study of the prevalence of Chinese restaurant syndrome. Fed Proc. 1977;36:1617–1623
  27. Tarasoff L, Kelly MF. Monosodium L-glutamate: A double-blind study and review. Food Chem Toxicol. 1993;31:1019–1035
  28. Yang WH, Drouin MA, Herbert M, et al. The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study. J Allerg Clin Immunol. 1997;99:757–762
  29. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am. 2001;85:911–941
  30. Walker R. The significance of excursions above the ADI (Case study: Monosodium glutamate). Regul Toxicol Pharmacol. 1999;30:S119–S121
  31. Henderson WR, Raskin NH. “Hot-dog” headache: Individual susceptibility to nitrite. Lancet. 1972;2:1162–1163
  32. Crandall LA, Leake CD, Loevenhart AS, et al. Acquired tolerance to and cross tolerance between the nitrous and nitric acid esters and sodium nitrite in man. J Pharmacol Exp Ther. 1931;41:103–119
  33. Moffett A, Swash M, Scott DF. Effect of tyramine in migraine: A double-blind study. J Neurol Neurosurg Psychiatry. 1972;35:496–499
  34. Ryan RE. A clinical study of tyramine as an etiological factor in migraine. Headache. 1974;14:43–48
  35. Ziegler DK, Stewart R. Failure of tyramine to induce migraine. Neurology. 1977;27:725–726
  36. Medina JL, Diamond S. The role of diet in migraine. Headache. 1978;18:31–34
  37. Eisenberg DM, Kessler RC, Van Rompay MI, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: Results from a national survey. Ann Intern Med. 2001;135:344–351
  38. Draves AH, Walker SE. Parthenolide content of Canadian commercial feverfew preparations: Label claims are misleading in most cases. Can Pharm J (PRC). 2003;136:23–30
  39. Hendriks H, Bos R, Woerdenbag HJ. The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour Fragr J. 1996;11:367–371
  40. Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet. 1997;350:1598–1599
  41. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev Issue. 2004;1:CD002286
  42. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: A systematic review. Cephalalgia. 1998;18:704–708
  43. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996;17:1–12
  44. Kuritzky A, Elhacham Y, Yerushalmi Z, et al. Feverfew in the treatment of migraine: Its effect on serotonin uptake and platelet activity. Neurology. 1994;44:293P
  45. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A placebo-controlled double-blind study. Phytother Res. 1997;11:508–511
  46. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:569–573
  47. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–192
  48. De Weerdt CJ, Bootsma HPR, Hendricks H. Herbal medicines in migraine prevention: Randomized double-blind placebo-controlled crossover trial of feverfew preparation. Phytomedicine. 1996;3:225–230
  49. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: A double-blind, multicenter, randomized placebo-controlled dose–response study. Cephalalgia. 2002;22:523–532
  50. Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25mg t.i.d. feverfew CO2−extract (MIG-99) in migraine prevention: A randomized, double-blind, multicenter, placebo-controlled study. Cephalalgia. 2005;25:1031–1041
  51. Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: A prospective, open-label study. Clin Drug Invest. 2006;26:287–296
  52. Diener HC, Schorn CF, Bingel U, et al. The importance of placebo in headache research. Cephalalgia. 2008;28:1003–1011
  53. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765–786
  54. Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: Is a full reproductive study warranted?. Reprod Toxicol. 2006;22:688–693
  55. NN. Tanacetum parthenium, ESCOP Monographs. Heidelberg: Thieme Publishers; 2003;pp 492-498
  56. Bucher K. [an antispastic principle in Petasites officinalis Moench.] (Naunyn Schmiedebergs). Arch Exp Pathol Pharmakol. 1951;213:69–71
  57. Fiebich BL, Grozdeva M, Hess S, et al. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med. 2005;71:12–19
  58. Brune K, Bickel D, Peskar BA. Gastroprotective effects by extracts of Petasites hybridus: The role of inhibition of peptido-leukotriene synthesis. Planta Med. 1993;59:494–496
  59. Thomet OA, Wiesmann UN, Schapowal A, et al. Role of petasin in the potential antiinflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol. 2001;61:1041–1047
  60. Wang GJ, Wu XC, Lin YL, et al. Ca2+ channel blocking effect of iso-S-petasin in rat aortic smooth muscle cells. Eur J Pharmacol. 2002;445:239–245
  61. Wu SN, Chen H, Lin YL. The mechanism of inhibitory actions of S-petasin, a sesquiterpene of Petasites formosanus, on L-type calcium current in NG108-15 neuronal cells. Planta Med. 2002;69:118–124
  62. Agosti R, Duke RK, Chrubasik JE, et al. Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: A systematic review. Phytomedicine. 2006;3:743–746
  63. Grossman M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther. 2000;38:430–435
  64. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern Med Rev. 2001;6:303–310
  65. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: Reanalysis of efficacy criteria. Eur Neurol. 2004;51:89–97
  66. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–2244
  67. Couch J, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36:695–699
  68. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol vs propranolol vs placebo in common migraine prophylaxis: A double-blind multicenter trial. Acta Neurol Scand. 1984;69:1–8
  69. Oelkers-Ax R, Leins A, Parzer P, et al. Butterbur root extract and music therapy in the prevention of childhood migraine: An explorative study. Eur J Pain. 2008;12:301–313
  70. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache. 2003;43:76–78
  71. Fox AW. “Safety” testing and herbal remedies. Headache. 2003;43:821–822
  72. Danesch U, Rittinghausen R. “Safety” testing and herbal remedies: Response. Headache. 2003;43:822–823
  73. Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache. 1991;31:298–301
  74. Mazzotta G, Sarchielli P, Alberti A, et al. Intracellular Mg++ concentration and electromyographical ischemic test in juvenile headache. Cephalalgia. 1999;19:802–809
  75. Mauskop A, Altura BT, Cracco RQ, et al. Deficiency in serum ionized magnesium but not total magnesium in patients with migraines (Possible role of ICa2+/IMg2+ ratio). Headache. 1993;33:135–138
  76. Mauskop A, Altura BT, Altura BM. Serum ionized magnesium in serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache. 2002;42:242–248
  77. Cady RK, Farmer K, Altura BT, et al. The effect of magnesium on the responsiveness of migraineurs to a 5-HT1 agonist (Presented at the American Academy of Neurology meeting, April 30, 1998, Minneapolis). Neurology. 1998;50(suppl 4):A340
  78. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5:24–27
  79. Peikert A, Willimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16:257–263
  80. Pfafferath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine-a double-blind, placebo-controlled study. Cephalalgia. 1996;16:436–440
  81. Mauskop A. Editorial: Evidence linking magnesium deficiency to migraines. Cephalalgia. 1999;19:766–767
  82. Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: A randomized, double-blind, placebo-controlled trial. Headache. 2003;43:601–610
  83. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial Neurology. 1998;50:466–470
  84. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache. 2004;44:885–890
  85. Tepper SJ. Alternative medicine in migraine: Is it ever a good alternative?. J Headache Pain. 2005;16:69–74
  86. Sándor PS, Afra J, Ambrosini A, et al. Prophylactic treatment of migraine with beta-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000;40:30–35
  87. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A. 1990;87:4879–4883
  88. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology. 2005;64:713–715
  89. Hershey AD, Powers SW, Vockell ALB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47:73–80
  90. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22:137–141
  91. Molyneux SL, Young JM, Florkowski CM, et al. Coenzyme q10: Is there a clinical role and a case for measurement?. Clin Biochem Rev. 2008;29:71–82
  92. Magis D, Ambrosini A, Sándor P, et al. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache. 2007;47:52–57
  93. McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: Overview of Program Description and Methodology. http://www.aan.com/professionals/practice/pdfs/gl0086.pdfAccessed May 14, 2009
  94. Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol. 2008;10:20–29

PII: S1084-208X(09)00009-3

doi: 10.1053/j.trap.2009.03.008

Techniques in Regional Anesthesia & Pain Management
Volume 13, Issue 1 , Pages 28-37 , January 2009

Article Tools